SMMT Summit Therapeutics Inc
Price (delayed)
$29.48
Market cap
$21.36B
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$21.44B
Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader
Highlights
The EPS has soared by 100% YoY
SMMT's equity has surged by 63% year-on-year
The net income has soared by 73% YoY but it has contracted by 39% from the previous quarter
Summit Therapeutics's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of SMMT
Market
Valuations
Earnings
Shares outstanding
724.54M
Market cap
$21.36B
Enterprise value
$21.44B
Price to earnings (P/E)
N/A
Price to book (P/B)
106.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$161.69M
EBITDA
-$160.44M
Free cash flow
-$97.61M
Per share
Balance sheet
Liquidity
EPS
$0
Free cash flow per share
-$0.14
Book value per share
$0.28
Revenue per share
$0
TBVPS
$0.48
Total assets
$341.86M
Total liabilities
$146.78M
Debt
$108.71M
Equity
$195.08M
Working capital
$188.63M
Debt to equity
0.56
Current ratio
2.35
Quick ratio
2.32
Net debt/EBITDA
-0.5
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-68.8%
Return on equity
-155.3%
Return on invested capital
-73.5%
Return on capital employed
-80.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SMMT stock price
How has the Summit Therapeutics stock price performed over time
Intraday
-7.67%
1 week
54.02%
1 month
154.14%
1 year
1,476.47%
YTD
1,029.5%
QTD
277.95%
Financial performance
How have Summit Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$158.71M
Net income
-$161.69M
Gross margin
N/A
Net margin
N/A
Summit Therapeutics's revenue has plunged by 100% YoY
The gross profit has dropped by 100% year-on-year
The net income has soared by 73% YoY but it has contracted by 39% from the previous quarter
The operating income has soared by 73% YoY but it has contracted by 38% from the previous quarter
Growth
What is Summit Therapeutics's growth rate over time
Valuation
What is Summit Therapeutics stock price valuation
P/E
N/A
P/B
106.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 100% YoY
SMMT's equity has surged by 63% year-on-year
Summit Therapeutics's revenue has plunged by 100% YoY
Efficiency
How efficient is Summit Therapeutics business performance
SMMT's return on invested capital has surged by 67% year-on-year but it is down by 41% since the previous quarter
The company's return on equity has surged by 67% YoY but it fell by 14% QoQ
The ROA has soared by 62% YoY but it has contracted by 24% from the previous quarter
Dividends
What is SMMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SMMT.
Financial health
How did Summit Therapeutics financials performed over time
SMMT's total assets is 133% more than its total liabilities
SMMT's total assets has soared by 93% from the previous quarter and by 44% YoY
The current ratio has dropped by 88% year-on-year and by 66% since the previous quarter
The debt is 44% smaller than the equity
Summit Therapeutics's debt to equity has plunged by 77% from the previous quarter and by 38% YoY
SMMT's equity has surged by 63% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.